Cereno Scientific signs agreement with University of Michigan to bring new preclinical candidate CS585 into clinical phase
Cereno Scientific today announced that a collaboration agreement for the full preclinical development program of the new drug candidate CS585 has been signed with the University of Michigan. The development agreement includes the successful transition of CS585 to a clinical Phase I program. The IND-enabling work will be conducted at the University of Michigan, a top-ranked public research university in the US with an extensive track record of successful collaborations with industry. CS585 is in development within cardiovascular diseases.“The preclinical development with CS585 will start